Clinical research
Shares of AstraZeneca dropped slightly Wednesday afternoon following reports that a patient participating in the Brazilian arm of the company’s global Phase III study has died.
Finding and developing an effective treatment for nonalcoholic steatohepatitis has, so far, been met with as much futility and frustration as developing a treatment for Alzheimer’s disease. Sagimet Biosciences Chief Executive Officer George Kemble believes his company is on the right path, though.
Biogen originally announced the initiation of its Phase II clinical trial, AFFINITY, designed to evaluate opicinumab back in 2017. The drug was being examined as an investigational add-on therapy for patients with relapsing MS.
The U.S. arm of the trial has been paused for more than a month while the U.S. Food and Drug Administration investigates a serious illness that occurred in a patient who received the experimental treatment.
Shares of Aptinyx skyrocketed more than 75% after the company reported its mid-stage experimental treatment for post-traumatic stress disorder demonstrated clinically meaningful and statistically significant results that will set up a pivotal study next year.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
Merck reported results from two more Phase III trials of V114, it’s 15-valent pneumococcal conjugate vaccine.
Intellia has received approval to launch their Phase I trial of NTLA-2001 in hereditary ATTR.
New data presented at the IASLC 2020 North America Conference on Lung Cancer shows a combination of Keytruda with other medications has a positive impact on non-small cell lung cancer.
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look.
PRESS RELEASES